EUTOS Home  · 

EUTOS for CML is a unique collaboration between the European LeukemiaNet and Novartis Oncology in Europe

The EUropean Treatment Outcome Study (EUTOS) is a collaboration between the European LeukemiaNet ELN and Novartis started in June 2007 running initially for 3 years to improve understanding of CML, promote best practise, and enhance treatment outcomes, through 4 key projects:

• CML registry
• Molecular monitoring
• Path to cure
• Spread of excellence

The initial collaboration has now been extended for two additional years (2011-2012), encompassing the following workstreams:

• CML registry
• Molecular monitoring
• Spread of excellence
• Path to Cure

Major aims of the cooperation are to:

• Enhance understanding of the nature and management of CML
• Optimize treatment of CML patients across Europe
• Improve standardized evaluation and monitoring of treatments for CML
• Promote cooperation among hematologists and scientists across Europe with the objective of moving along the path to cure CML
• Foster continued medical education and spread of excellence on CML and EUTOS

Created by: A. Hellenbrecht , generated 2007/12/19 , last changed: 2011/07/21